Kura Oncology's ziftomenib shows promise in AML treatment, with key data readouts expected in 2025, but faces competition from Syndax's revumenib. Kura's strong cash position supports operations ...
Live audio webcasts will be available in the Investors section of Kura’s website at https://kuraoncology.com/, with archived replays available following all three ...
Kura Oncology (NASDAQ:KURA) stock slid 7% in post-market trading after the company issued an update on its drug ziftomenib. Kura (NASDAQ:KURA) reported positive Phase 2 data from a registration ...
Kura Oncology (KURA) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $0.55 per share a year ago. These figures ...
1mon
Kura Oncology, Inc. (the "Company") (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback